Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 July 2006

Outcome and prognosis of severe thrombotic microangiopathies treated by plasmaexchange.

Laure Federici, Kada Klouche, Laurent Amigues, Tarik Kanouni, Ernesto Lopez-Martinez, Pascal Latry, Jean Jacques Beraud, Jean Francois Rossi

Med Sci Monit 2006; 12(7): CR302-307 :: ID: 452202


Background: Plasma exchange (PE) therapy has dramatically improved theoutcome of thrombotic microangiopathies (TMA) in adults. However, resistance to PE, which indicates apoor prognosis, is observed in 1/3 of patients and remains not fully understood. We evaluated in thisstudy the survival and the long-term outcome of severe TMA treated by PE and identified the predictivefactors of resistance to PE and of mortality. Material/Methods: Records of adults with severe TMA treatedby PE were reviewed. Clinical and biological data, therapeutic delay to PE, plasma volume exchange perprocedure, and number of PE sessions were collected. Mortality was assessed at one month and at one-yearfollow-up. All data were analyzed and compared between survived/deceased and between responder/non-responderpatients. Results: Nineteen females and six males were included. Mean age (+/-SD) was 46.8+/-16.3 years,Glasgow coma score 11+/-3, and Sequential Organ Failure Assessment (SOFA) score 5.8+/-2.8. Nineteen patientspartially or fully responded to PE. Twenty patients were alive at one month and 19 at one year. The responseto PE was the single discriminating parameter between survivors and non-survivors. A longer delay ofPE and a neoplastic cause of TMA were significantly higher in the non-responders. Conclusions: SevereTMA treated by PE had a fair prognosis, with a survival rate at 76% after one year of follow-up. Unresponsivenessto PE was the only predictive factor of mortality; a neoplastic etiology of TMA and a longer therapeuticdelay of PE were predictive of resistance to PE.

Keywords: Plasma Exchange, Thrombosis - therapy, Vascular Diseases - therapy

Add Comment 0 Comments


01 April 2024 : Editorial  

Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance

Dinah V. Parums

DOI: 10.12659/MSM.944600

Med Sci Monit 2024; 30:e944600


In Press

06 Mar 2024 : Clinical Research  

Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943884  

08 Mar 2024 : Clinical Research  

Evaluation of Foot Structure in Preschool Children Based on Body Mass

Med Sci Monit In Press; DOI: 10.12659/MSM.943765  

15 Apr 2024 : Laboratory Research  

The Role of Copper-Induced M2 Macrophage Polarization in Protecting Cartilage Matrix in Osteoarthritis

Med Sci Monit In Press; DOI: 10.12659/MSM.943738  

07 Mar 2024 : Clinical Research  

Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...

Med Sci Monit In Press; DOI: 10.12659/MSM.943468  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750